A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

• Verfasst von: Manegold, Christian [VerfasserIn]
• Titel: A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
• Verf.angabe: C. Manegold, N. van Zandwijk, A. Szczesna, P. Zatloukal, J. S. K. Au, M. Blasinska-Morawiec, P. Serwatowski, M. Krzakowski, J. Jassem, E. H. Tan, R. J. Benner, A. Ingrosso, S. J. Meech, D. Readett and N. Thatcher
• Jahr: 2012
• Umfang: 6 S.
• Fussnoten: Published online 4 April 2011 ; Gesehen am 12.09.2018
• Titel Quelle: Enthalten in: Annals of oncology
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 1990
• Jahr Quelle: 2012
• Band/Heft Quelle: 23(2012), 1, Seite 72-77
• ISSN Quelle: 1569-8041
• DOI: doi:10.1093/annonc/mdr030
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1580908543

Abstract

Committee recommended study discontinuation. Administration of PF-3512676 was halted based on efficacy futility and increased grade ‡3 AEs (experimental arm). Conclusions: Addition of PF-3512676 to gemcitabine/cisplatin chemotherapy did not improve OS or PFS but did increase toxicity.